Vantage Health partners with government to set up pharma plant in Swaziland

26 July 2011

South Africa-based Vantage Health (OTC.BB: VNTH) says that it has been invited by the Swaziland Ministry of Health to plan the construction of a pharmaceutical manufacturing facility in that country.

In a letter to the company, Swaziland's Minister for Health. Benedict Xaba, said: "…Should you expedite your interest, we will enter into off-take agreements for the pharmaceuticals produced in the newly established Swaziland pharmaceutical plant." The Minister also confirmed that the Kingdom would assist Vantage and its technology partners "with all relevant regulatory required processes regarding the successful implementation of this most important project."

Following Vantage's recent entrance into the Tanzanian health care space through its 51% ownership of Vantage Health Tanzania, the company intends to immediately establish an additional majority owned subsidiary in Kingdom of Swaziland, in line with its pan-African Plan for Expansion

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK